Columbia Laboratories (CBRX) Finishes Treatment Phase of PROCHIEVE Phase III Study
More News related to CBRX
- Columbia Labs (CBRX) Completes 1.3M Share Offering; Raises $4.1M in Net Proceeds
- Columbia Laboratories Closes Registered Direct Common Stock Offering
- Columbia Laboratories (CBRX) Prices 1.3M at $3.50 for Proceeds of $4.1M
- Columbia Laboratories Announces Registered Direct Common Stock Offering
- Rodman & Renshaw Initiates Columbia Labs (CBRX) with a Market Outperform
More News related to FDA
- Celgene (CELG) Down On Talk of REVLIMID Warning
- Orthofix International (OFIX) Receives FDA 510(k) Approval
- Rosetta Genomics (ROSG) Identifies Potential microRNA Biomarkers in Blood Serum
- BioCryst Pharma (BCRX) Reports Results From BCX-4208 Phase IIa Trial in Subjects With Psoriasis
- Celgene (CELG) Granted FDA Fast Track Designation for Amrubicin
Columbia Laboratories, Inc. (NASDAQ: CBRX) announced it has completed the treatment phase of its pivotal Phase III clinical study of PROCHIEVE 8% (progesterone gel) to prevent recurrent preterm birth. This 669-patient randomized, double-blind, placebo-controlled clinical trial is the largest preterm prevention study ever conducted. The ultimate goal of this program is to expand the PROCHIEVE 8% label beyond infertility and secondary amenorrhea, for which it is currently FDA-approved and commercially available, to include the prevention of recurrent preterm birth.
Related Categories
FDAStocks Mentioned
-0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
